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INTRODUCTION 
During the past 20 years, the world pharmaceutical industry has experienced a dramatic 
increase in R&D intensity. In a recent paper, Grabowski and Vernon (2000) explore the 
determinants underlying this trend in R&D investment behaviour for a pooled sample of 11 
major U.S. drug firms over the period 1974 to 1994. Estimating a static panel data model, 
they find that expected returns and cash flow are important explanatory variables of firm 
research intensities during this period. 
 
In this paper, we explore whether similar conclusions also hold for the Japanese 
pharmaceutical industry. Given institutional differences and the differences in the way how 
firms are funded in the U.S. and Japan, there is good reason to expect divergent results. In 
particular, the U.S. is the only drug market in the world where prices are unregulated, and 
financial systems are quite different in the two countries. 
 
Using a pooled data sample of the 15 publicly listed (and largest) Japanese drug firms for the 
period 1987 to 1998, we start out with the baseline model estimated by Grabowski and 
Vernon (2000). We then extend their model to accommodate for special features of the 
Japanese drug market and for econometric issues not dealt with in the reference paper. This 
aligns our results with the existing general literature on the determinants of investment in 
R&D. 
 
We find expected returns to be an important determinant of R&D spending in the Japanese 
pharmaceutical industry. In absolute terms, however, R&D spending is considerably less 
responsive than in U.S., in particular in a dynamic panel data model, which is a theoretically 
more appropriate specification. Likewise, sensitivity to cash flow is considerably smaller in 
Japan and disappears in the dynamic model formulation, confirming the result of other studies 
that Japanese firms face fewer or even no financial constraints. 
 
The paper is structured as follows. In Section 0, we briefly highlight the particular features of 
R&D, which impact the R&D investment decision. In Section III, we describe recent trends in 
pharmaceutical R&D in Japan and discuss the particularities of the Japanese drug market. In 
Section 0, we present the data and discuss our econometric model specifications. In Section 0, 
we list and interpret our estimation results. Section 0 summarises the paper and concludes 
with directions for future research. 
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THE R&D INVESTMENT DECISION 
According to basic economic theory, a firm's R&D investment decision is determined by the 
intersection of the marginal rate of return on investment schedule and the marginal cost of 
capital schedule. These are obtained by arranging potential investment projects in order of 
decreasing rates of return and the opportunity costs of alternative investment in increasing 
order. However, investment in R&D differs from ordinary investment in a number of 
fundamental ways, which impact the way investment in R&D is modelled. 
 
First, and perhaps most importantly, a significant share of R&D spending are wages and 
salaries of scientists and engineers, who create ideally profitable new knowledge. This 
knowledge is specialized, sunk and intangible, and its value hence very difficult to determine. 
 
Second, even to the extent that R&D produces tangible output, its ultimate value is uncertain 
and difficult to appraise ex-ante. Time horizons may be quite long, as in the pharmaceutical 
industry, where it takes 14 years on average at present to develop and introduce a new 
chemical entity (NCE) (see PhRMA 2003). Not only is the variance of the distribution of 
expected returns much larger than for other types of investment. Rather, returns to R&D are 
highly skewed (Scherer et al. 2000) and appear to be fat-tailed, which may affect the 
computation of moments. In a recent paper, Silverberg and Verspagen (2005) estimate Pareto 
exponents <1 for various empirical data sets, showing that not even the first central moment 
(the mean) converges in these cases. In such situations, meaningful expected-rates-of-return 
cannot be calculated and standard risk-adjustment methods do not work any more. 
 
Third, the cost of capital may differ considerably by source of funding. Empirical evidence 
typically shows a positive association between R&D spending and cash flow, indicating a gap 
between the external and the internal costs of capital (for surveys, see Hubbard 1998; Hall 
2002). Economic theory provides three main types of explanations: (i) asymmetric 
information between inventor and investor, (ii) moral hazard on the part of the inventor and 
(iii) distortions introduced by the tax system. 
 
Information asymmetries arise because firms undertaking R&D tend to be better informed 
about the quality and prospects of their R&D projects than outside investors. These may 
therefore require a 'lemons' premium' (after Akerlof's (1970) seminal model of adverse 
selection) to cover the extra risk they incur, which raises the cost of external capital. Moral 
hazard stems from the principal-agent relationship between a firm's owner(s) and its 
managers. Because of imperfect monitoring, managers may either overinvest free cash flow in 
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activities that benefit them (enhance their income, status, job security, etc.) or underinvest 
free cash flow in uncertain R&D projects. In both cases, share-value is not maximised and 
there is an agency-cost induced gap between the cost of capital and the return to R&D.  
Distortions introduced by the tax system are due to different levels of taxes levied on retained 
earnings, debt and equity. Typically, interest on debt can be expensed, while retained earnings 
are subject to capital gains tax, and new share issues are subject to personal tax and capital 
gains tax on dividends. However, debt is usually serviced from cash flow, which reduces the 
amount available to sustain a productive R&D programme. This opportunity cost may more 
than offsets any tax advantage of debt, rendering retained earnings the cheapest source of 
funding R&D. The surveys by Hall (2002) and Hubbard (1998) list ample empirical evidence 
in support of each of these theoretical arguments. 
 
Empirical studies show that financing constraints are mediated by the institutional set-up of 
countries' financial system. Bond et al. (2003) compare the impact of cash flow on physical 
and R&D investment in Britain and Germany in the high-tech sector over the period 1985-
1994. They find significant constraints in the UK but not in Germany, which they attribute to 
differences induced by the stock-exchange based system in the UK and the bank-based 
system in Germany. Mulkay et al. (2001) compare the U.S. with France and find that internal 
funds are more important for physical and R&D investment in the USA than in France. Hall 
et al. (1999) analyze large samples of firms in R&D intensive industries in the USA, Japan 
and France. They find that investment in fixed capital and R&D are sensitive to cash flow 
only in the USA. Their results support the notion that firms in France and Japan face weaker 
financing constraints. 
 
The theoretical considerations have two consequences for modelling the R&D investment 
decision. First, depending on the institutional framework they are operating in, firms are not 
indifferent to their source of funding. Rather, capital market imperfections yield the marginal 
cost of capital (mcc) curve depicted schematically in Figure 1. It consists of two horizontal 
segments, one representing the lower cost of internal funds (free cash flow) and the other the 
higher cost of new equity financing. The rising connecting segment stands for the cost of new 
debt financing. R*, the optimal amount of R&D investment is given by the intersection of the 
marginal rate of return (mrr) and the mcc curve. Obviously, an increase in free cash flow 
shifts the mcc schedule to the right (mcc') which raises R* to R*'. Similarly, higher expected 
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returns to R&D shift the mrr schedule upwards (mrr'), also raising the optimal amount of 
R&D investment to R*'3. 
Figure 1: The R&D investment decision 
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Source: adapted from Grabowski and Vernon (2000, pp. 207-208) 
Second, in light of the characteristics of R&D investment described above, there are reasons 
to expect an autonomous component in R&D investment behaviour. The more difficult it is to 
compute an exact measure of the expected returns to R&D, the more likely it is that firms will 
apply simple decision rules to determine their R&D investment (e.g. a certain share of 
revenues). An additional element of sluggishness is introduced by the fact that R&D enhances 
firms' knowledge bases, which is mainly embodied in their employees, especially their R&D 
personnel. If these leave or are dismissed, firms may lose valuable resources. So as to hold on 
to them, firms tend to smooth their R&D investment over time (see Hall 2002). 
 
The foregoing discussion has highlighted the pivotal role of institutional factors for firms' 
R&D investment behaviour. Before specifying our model, we therefore need some 
background information on R&D in the Japanese pharmaceutical industry. This will be given 
in the next section. 
                                                     
3  For expositional clarity, we show only shifts of either the mcc or the mrr curve of 
equal size, yielding the same new optimum R*'. 
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R&D IN THE JAPANESE PHARMACEUTICAL INDUSTRY 
R&D in the pharmaceutical industry is driven by the search for the next 'blockbuster' drug. 
These 'blockbusters' are a very small number of highly innovative drugs that account for a 
disproportionate share of profits realised by individual firms and the entire industry 
(Grabowski and Vernon 1994). For example, the three leading products in 2002 – Lipitor and 
Zocor, two cholesterol lowering drugs, and Losec/Prilosec, an anti-ulcer drug – had global 
sales of USD 20.0 billion (IMS HEALTH 2003). Since the late 1970s, the rate of such major 
drug innovations has increased significantly (see Grabowski and Vernon 2000). This is due to 
greater technological opportunity, brought about by major process innovations4 in the way 
how R&D is conducted and more targeted search thanks to advances in scientific 
understanding. 
 
This trend has coincided with a dramatic increase in R&D spending by pharmaceutical firms. 
As shown by PhRMA (1999), aggregate R&D intensity (R&D-to-sales ratios) has almost 
doubled from 10.9 to 20.0% between 1974 and 1998. A similar trend is also observable in 
Japan (see Figure 2), where the aggregate R&D-to-sales ratio of the 15 largest publicly listed 
pharmaceutical firms has risen from 9% in 1987 to 13.5% in 1998 in an almost linear fashion. 
Which factors stand behind this development? For the U.S., Grabowski and Vernon (2000) 
identify two variables, expected returns to R&D and cash flow. They argue that thanks to the 
higher number of major new drug innovations expected returns to R&D investment have 
increased in recent years, while the expanding industry cash flow generated by these 
innovations has provided a readily available (and relatively low cost) source of funds to 
finance R&D (Grabowski and Vernon 2000, pp. 205-206). Can a similar argument also be 
made for Japan? 
 
Which factors stand behind this development? For the U.S., Grabowski and Vernon (2000) 
identify two variables, expected returns to R&D and cash flow. They argue that thanks to the 
higher number of major new drug innovations expected returns to R&D investment have 
increased in recent years, while the expanding industry cash flow generated by these 
innovations has provided a readily available (and relatively low cost) source of funds to 
                                                     
4  These include combinatorial chemistry, through which structurally related molecule 
variations are mass-produced through the parallel synthesis of combinations from any number 
of starting substances, high throughput screening, the parallel testing of a very large number 
of compounds in parallel at a micro scale by automated robots, and the use of ever more 
powerful computers and computer software, which allow to analyse the wealth of available 
information in more comprehensive ways, and – along with breakthroughs in visualisation 
technology – help to accelerate the growth of scientific understanding. 
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finance R&D (Grabowski and Vernon 2000, pp. 205-206). Can a similar argument also be 
made for Japan? 
Figure 2: Aggregate R&D-to-sales of 15 publicly listed Japanese drug firms 
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Source: Morgan Stanley Dean Witter (1998) 
As opposed to their international rivals, Japanese pharmaceutical companies generate most of 
their revenues domestically. For example, in 1997, the export ratio of the top ten Japanese 
drug firms ranged from 2.3% (Shionogi) to 18.6% (Sankyo). In comparison, in the same year, 
Bristol Myers Squibb generated 31.9% of its revenues abroad and Novartis even 98.1% 
(Morgan Stanley Dean Witter 1998). Therefore, the economic decisions of Japanese drug 
firms are almost exclusively determined by the situation in their home market. 
 
In principle, drug market fundamentals are very favourable in Japan. Along with France, 
Japan has the highest per capita drug consumption among OECD countries. In 1997, drugs 
accounted for 21% of total health spending in Japan, compared to merely 8.4% in the U.S. 
(OECD 1997). The share of senior citizens (aged above 65), who account for more than half 
of total drug consumption, is predicted to rise from 17% in 2000 to 26% in 2025, the highest 
share among OECD countries (Koseisho 1996). This matters even more as health-related 
expenditures tend to rise with age and senior Japanese citizens spend almost five times more 
than those aged below 65 (Oliver et al. 1997). As a result, the Japanese Ministry of Health 
estimates that health spending will rise by around 150% in real terms between 1997 and 2025. 
The reason why Japanese take so many pills lies in the way how prices are determined and 
how drugs are distributed. Drug prices are set by the Central Social Insurance Medical 
Council (chuikyo). Distribution mainly takes place via doctors rather than pharmacies. This 
gives the former an incentive to liberally prescribe drugs, especially those with high profit 
margins. These margins, called yakka-saeki, arise from the difference between wholesale 
prices and official list prices, set by chuikyo, at which doctors are reimbursed by the health 
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insurance companies. For the year 1987 only, the margin was estimated to be in the order of 
USD 9 billion (Reich 1990) to USD 13 billion (Hisashige 1997). 
 
In order to reign in the exploding health bill, the Ministry of Health regularly checks 
pharmaceutical firms' and wholesalers' books to determine the difference between market and 
list prices and adjusts the latter to the former. This leads to biannual price cuts (on average) of 
sometimes more than 10%. These price cuts do ease pressure on the public health bill, but 
have significant impacts on the drug market. Because of the downward price spiral, the 
average life span of a drug is considerably shorter than elsewhere. While the average drug is 
sold for 10.8 years in the U.S. and 12.9 years in the UK, this period is only 7.9 years in Japan 
(Huttin 1995). Shorter drug lifecycles reduce the incentive to undertake extremely risky and 
expensive investments in breakthrough medicines, which require long pay-back periods to 
cover their development costs. An 'innovation premium', introduced in 1992 and increased in 
1996, which grants price surcharges to new innovative medicines of up to 60% compared to 
existing substitutes, has not altered the situation. As a result, only 13% of 'significant new 
drugs' that were registered and distributed in at least six countries were made available in 
Japan between 1995 and 1998 (Thomas 2001). 
 
Because of the lower market potential of innovative medicines, technological novelty is less 
important than skilful marketing for commercial success. This is illustrated by the fact that 
45% of the employees of Japanese pharmaceutical firms work in marketing or sales 
departments, compared to 30% in the U.S. (McLellan 1997). As a consequence, we expect 
new drug sales to be a relatively smaller stimulus for R&D investment in Japan than 
Grabowski and Vernon find in the U.S. 
 
Hypothesis 1: Because of the regulatory environment, R&D investment in Japan is 
insufficiently rewarded. The success of a new medicine is less a function of its innovative 
content than of a host of other factors, above all marketing expenditures. Therefore, we 
expect a smaller elasticity of R&D investment with regard to sales of new drugs than in the 
United States. 
 
The second explanatory variable considered by Grabowski and Vernon (2000) is the 
availability of cash flow. As argued above, most R&D is funded internally as markets for 
financing R&D tend to be incomplete. In this context, venture capital may be a cheap external 
source of funding, which has become particularly important in funding small, mostly science-
based new and young firms (such as in the biotech industry). However, the firms we study in 
this paper are large and established pharmaceutical companies. Moreover, during the period 
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considered in this paper, the venture capital industry was far less developed in Japan than in 
the U.S. or (even) Europe (see OECD 2001). 
 
Grabowski and Vernon (2000) show that the availability of cash-flow has increased in recent 
years in the U.S. pharmaceutical industry, providing ample funding opportunities. Although 
this is also true of Japan (see Figure 3), there are reasons to expect that Japanese firms are less 
reliant on cash flow in their investment decisions than their U.S. rivals. 
Figure 3: Aggregate cash-flow/sales, 1987-1998 
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Source: Morgan Stanley Dean Witter (1998) 
Japan's financial system is bank-based, rather than stock-exchange based as in the U.S. In a 
bank-based financial system, the main source of external funding is banks, both for private 
firms and the small number of publicly listed large firms. Bank lending is relational, i.e. each 
loan is seen as part of a long-term relationship in which a firm grants the bank full access to 
its books in return for influence over its policy and personnel and committed support through 
bad times. Much lending is long-term and where firms borrow from more than one bank, one 
of them is usually recognised as 'lead' or 'house' bank and maintains oversight of the firms' 
financial positions (Tylecote 1994, p. 261). This is particularly true of keiretsus, large 
industrial groupings organised around a bank. These are mainly based on financial aspects 
(provision of loans, mutual shareholding, etc.) and opportunities to exchange information, 
rather than the transaction of goods (Miarka 1999, p. 4). 
 
To the extent that the close ties between firms and banks allows better monitoring and reduces 
information asymmetries, the cost of external funds are lower (confirmed empirically by 
Miarka 1999) and cash flow has a smaller effect on investment, holding constant investment 
opportunities (see Hubbard 1998; Hall et al. 1999). For Japan, it has indeed be shown that 
liquidity effects on investment are (at least historically) less important for firms belonging to 
a keiretsu than for firms that are not part of such a group (see Hoshi et al. 1991). Also, those 
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firms with access to a bank should have lower costs of capital because of lower information 
costs, which should increase returns in the long run. Historically, this indeed used to be true 
of returns on R&D investments in Japan (e.g. Griliches and Mairesse 1990). For a recent 
survey on firm-bank relationships in Japan see Hoshi and Kashyap (2001). 
 
Hypothesis 2: Thanks to their close ties with banks, Japanese firms have ready access to 
relatively cheap and long-term external funds. As a consequence, the R&D investment 
decision of Japanese firms is less dependent on internally generated cash flow. Therefore, we 
expect a smaller elasticity of R&D investment with regard to the availability of free cash flow 
than in the United States. 
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DATA AND ECONOMETRIC MODEL SPECIFICATIONS 
In the following, we will test the two hypotheses with data on Japan for the period 1987-1998. 
Our sample consists of all 15 publicly listed Japanese pharmaceutical firms, i.e. Banyu, 
Chugai, Daiichi, Eisei, Fujisawa, Kissei, Ono, Sankyo, Santen, Shionogi, Seikagaku, Taisho, 
Takeda, Tanabe and Yamanouchi. Firm and market data have been obtained from Morgan 
Stanley Dean Witter Tokyo. 
For comparative purposes, we start out with the baseline model estimated by Grabowski and 
Vernon (2000), 
( )1, −= ittit CFSEfRDS π , 
where RDSit is R&D normalised by sales for firm i in year t, Eπt is an index of expected 
returns to R&D in pharmaceuticals in year t, and CFSt-1 is cash flow divided by sales for firm 
i in year t-1. 
 
The typical proxy for investment opportunities in the literature is Tobin's q or some variation 
of it (see Gugler et al. 2003). However, this is an unspecific measure for all types of 
investment. In this paper, we prefer to use measures that capture expected returns to R&D 
more specifically. We use two measures for the Eπt variable. The first measure, NEWSALES, 
is a kind of industry level R&D productivity index, which is defined as the sum of estimated 
peak revenues from new drug introductions in year t, divided by aggregate real R&D 
expenditures in year t.5 Peak revenue estimates are from Morgan Stanley Dean Witter. 
According to analysts, this measure sufficiently describes the entire revenue life cycle of a 
drug. It is assumed that a high R&D productivity at the industry level lets managers become 
more optimistic about their firms' prospects and induces them to raise R&D spending. 
Moreover, firms may benefit from knowledge generated by other firms' R&D efforts (see 
Henderson and Cockburn 1996). 
 
NEWSALES captures the productivity of current R&D in terms of sales generated by new 
drug introductions. The second measure, INDMARG (short for industry margin), is the 
weighted average profit rate of the entire industry, expressed as pre-tax profits divided by 
sales. It captures the price-cost margin of sales of both new and established products. While 
being a function of R&D performance, it also reflects other economic forces affecting the 
industry, in particular the impact of regulatory interventions. Since the value of R&D output 
                                                     
5  Note that Grabowski and Vernon (2000) construct NEWSALES as a measure of 
recent R&D productivity by using lagged values. Although preferable from a theoretical point 
of view, data constraints prevented a similar construction in this paper. 
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is highly uncertain and difficult to determine, and managers therefore do not know about the 
future profitability of their firms, we assume that expectations are formed on the basis of the 
most recent available data. We assume that if industry margins rise, managers become more 
optimistic about their firms' fate and raise R&D spending. 
 
Figure 4 plots the NEWSALES and INDMARG variable. It shows that measured by the 
NEWSALES variable, industry R&D productivity has declined during the observation period. 
This is in stark contrast with the U.S., where Grabowski and Vernon (2000) find a rising trend 
from the mid-1970ies to the mid-1980ies and a stable performance at a high level until the 
mid-1990ies. Furthermore, Figure 4 shows that although somewhat less profitable in absolute 
terms, Japanese pharmaceutical firms have recorded a comparable increase in industry profit 
margin as their U.S. peers during the observation period. 
Figure 4: NEWSALES and INDMARG index, 1987-1998 
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Source: Morgan Stanley Dean Witter (1998), own calculations 
Breaking down the variable by its components (see Figure 5) shows a constant to falling 
number of innovative NCEs being introduced each year. Similarly, sales per new products 
rather decline over time. 
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Figure 5: Number of new drug introductions and generated peak sales 
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Source: Morgan Stanley Dean Witter (1998) 
The third variable in this regression model, CFSt-1, is the cash flow-to-sales ratio in period t-1. 
Cash flow is computed as the sum of net profits before dividend payments, depreciation and 
after-tax R&D expenditures. Since R&D is expensed for tax purposes, one must add back 
'after-tax R&D outlays' to arrive at correct pre-investment cash-flows (Hall 1992). After-tax 
R&D expenditures are computed as (1-TE) x I, where TE is the effective tax rate and I is R&D 
spending.6 Figure 3 above, which plots the evolution of the aggregate CFS variable for all 
firms, shows an increase for most of the years during the observation period, with brief 
slumps in 1991, 1992 and 1997. 
 
To account for unobserved heterogeneity in our sample we estimate a fixed-effects 
specification of our baseline model, 
itiitititit NEWSALESCFSINDMARGRDS εαβββ ++++= − 3121  (1) 
                                                     
6  Company taxes in Japan consist of 'corporate taxes' and 'local taxes', which are 
collected by the cities and prefectures. 'Corporate taxes' for companies with an equity capital 
of more than Yen 100 million have been 30% of profits since April 1, 2000 (formerly 34.5%). 
Smaller firms with an equity capital of less than Yen 100 million pay 20% taxes (formerly 
25%) on profits of up to Yen 8 million. Apart from the corporate tax, there is an 'enterprise 
tax' of 12% and a 'resident tax', which consists of two parts: 1. A 'prefecture tax', which 
amounts to 5% of the 'corporate tax', i.e. 30% x 5% = 1.5%. 2. A 'city tax', which is 12.3% of 
the 'corporate tax', i.e. 12.3% x 30% = 3.69%. The total nominal tax rate thus amounts to 
47.69%. However, since the 'enterprise tax' can be deducted from the tax base, the effective 
tax rate is only 42.13%. An example: For a profit of Yen 100, the tax base is 89.29 
[100/(1+0.12)]. 'Corporate taxes' amount to Yen 26.79 (89.19 x 30%) and 'enterprise taxes' 
are Yen 10.71 (89.29 x 12%). The 'prefecture taxes' are Yen 1.34 (26.79 x 5%) and the 'city 
tax' is Yen 3.29 (26.79 x 12.3%). The information on the Japanese tax system has been 
obtained from Tadahisa Koga from NISTEP, Tokyo. 
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where αi is the firm-specific, time-invariant constant term. A Hausmann specification test 
shows no difference between a fixed- and a random effects specification. Therefore, we focus 
on the fixed-effects model, which can be estimated by straightforward OLS. 
 
As a first extension of Model 1, we add two control variables. To control for the impact of 
normalising R&D by sales, we introduce firm sales as right-hand side variable SALES. There 
is an extensive literature on the relationship between R&D spending and firm size, known as 
the 'Schumpeter hypothesis' (for a survey, see Cohen 1995). Most studies find a U-shaped 
relationship with small and very large firms being relatively more R&D intensive (subject to 
inter-industry variations, see e.g. Acs and Audretsch (1991)). Japanese pharmaceutical firms 
are large by conventional measures, yet small by international standards. What this implies 
for R&D intensity is an open question a-priori. 
 
To capture the impact of the biannual price cuts described in Section 0, we construct a second 
control variable, dubbed SURPRISE, which measures the difference between actual and 
expected price reductions. Although firms know that prices are cut in odd years, they do not 
know by how much. We assume that firms form their expectations by averaging all price cuts 
from time tstart, our first observation, to t-1. In even years, when no price cuts are expected, 
SURPRISE takes on the value 0. Since price cuts are announced at the beginning of each todd, 
and the other variables we use are reported at the end of each year, we do not lag the variable 
in our estimations. We expect that larger-than-expected price reductions have a negative 
impact on R&D intensities as managers become less optimistic about future market 
conditions. 
 
Adding the two control variables, we thus estimate  
ititititititit SURPRISESALESNEWSALESCFSINDMARGRDS εαβββββ ++++++= − 543121  (2) 
as our second model. 
 
Next, we further extend Model 2 to correct for possible serial correlation in the error terms. 
Most time-series data is correlated over time, and in such a situation the OLS estimator no 
longer yields an unbiased estimate of the variance-covariance (VC) matrix. Although 
parameter estimates remain asymptotically unbiased, the biased VC matrix affects interval 
estimates and makes hypothesis testing unreliable. The classical solution to this problem in 
the standard regression model is to include an AR(1) term to remove any first-order 
autocorrelation in the disturbances εit. Baltagi and Wu (1999) develop a feasible generalised 
least squares (FGLS) procedure that applies this solution to the panel data case. For equally 
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spaced data with no missing observations, their model is equivalent to a Prais-Winsten 
transformation in the AR(1) model. The error term εit is modelled as itit z+−1ρε , with ρ<1 
and zit distributed identically and independently. There are several ways to specify ρ. In our 
case, ρ is defined as 1-DW/2, where DW is the Durbin-Watson d statistic. Apart from solving 
the econometric problem caused by first-order autocorrelation, the method has the additional 
advantage of keeping the model comparable to our baseline model. Model 2 thus becomes 
itititititititit zSURPRISESALESNEWSALESCFSINDMARGRDS +++++++= −− 1543121 ρεαβββββ
 (3) 
Models 1–3 are static specifications. However, theoretical considerations suggest that 
dynamic model in which lagged R&D spending appears on the right-hand side may in fact be 
a more appropriate specification. As highlighted in Section 0, R&D investment behaviour 
may have a strong autonomous component and be much less responsive to external variables 
than a static model would suggest. We therefore also consider a dynamic model of the form 
iittititititit RDSSURPRISESALESNEWSALESCFSINDMARGRDS εαββββββ +++++++= −− 16543121
 (4), 
where RDSt-1 is R&D spending normalised by sales lagged by one period. 
In estimating this model, we have to depart from the LS-framework because of the potential 
endogeneity of the lagged dependent variable and the presence of other potentially 
endogenous right hand side variables. Instead, we will use the systems GMM estimator 
developed by Blundell and Bond (1998) and applied in a similar context by Bond et al. 
(2003). For panels that are short in time and include persistent time series (such as our data 
set), Bond (2002) has shown that this estimator produces more efficient results in finite 
samples than standard GMM estimators which eliminate unobserved firm-specific effects by 
taking first differences (see Arellano and Bond 1991). The Blundell-Bond estimator combines 
in a system the regression in differences with the regression in levels. The instruments for the 
regression in differences are the lagged levels of variables consistent with the moment 
conditions. For the other component of the system, the equation in levels, the instruments are 
given by the lagged differences of the variables (see Bond 2002 for an accessible exposition 
of the estimation technique). 
 
We utilise the two-step variant of the Blundell-Bond system GMM estimator. This is 
asymptotically more efficient than the one-step variant, yet produces estimates of the standard 
errors that are biased downwards. Therefore, we apply the finite-sample correction to the two-
step VC matrix developed by Windmeijer (2005) that leads to more accurate finite sample 
inference. 
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ESTIMATION RESULTS AND INTERPRETATION 
The estimation results are displayed in Table 1. For comparative purposes, we show the 
results of the baseline model estimated by Grabowski and Vernon (2000) in the first column. 
For all model specifications, an F-test rejects the hypothesis that all parameters are equal to 
zero. In Model 3, a ρ value of 0.575 validates our conjecture of significant first-order serial 
correlation. In Model 4, the coefficient of the lagged dependent variable is close to unity, 
which supports our choice of the system GMM estimator. For the two-step systems GMM 
estimation, the Hansen J statistic, which is robust to non-spherical disturbances, indicates that 
the orthogonality conditions underlying the GMM estimator are valid. Goodness-of-fit 
measures (R2) are remarkably high for panel data estimation. Estimation results are quite 
robust across the different specifications, which makes us fairly confident as to the validity 
and reliability of our findings. 
 
Turning to our first hypothesis, parameter estimates for INDMARG are statistically 
significant in each of the specifications and produce quite sizeable absolute effects. For the 
static specifications (Models 1–3), they range from 0.322 to 0.532. Controlling for firm size 
and the impact of the pricing regime does not have a substantial impact on parameter 
estimates. However, including an AR(1) term in Model 3 nearly doubles the parameter 
estimate of the baseline model. In the dynamic specification (Model 4), the coefficient for 
INDMARG declines to 0.18, which was to be expected from controlling for autonomous 
R&D investment behaviour. Since INDMARG is the fraction of industry pre-tax profits 
divided by industry sales, our estimates suggest that a 1% increase (decrease) in industry 
profit margin will lead to an approximate 0.17 to 0.53% increase (decrease) in R&D 
expenditures, which is about one quarter to two thirds the impact estimated by Grabowski and 
Vernon for the U.S. 
Table 1: Regression output 
 G&V (2000) Model 1 Model 2 Model 3 Model 4 
Constant -0.18 (10.32) *** 6.296 (4.09)*** 6.898 (3.68)*** 3.408 (3.72) *** -1.58187 (0.95) 
INDMARG 0.77 (9.47) *** 0.322 (4.09)*** 0.329 (4.14)*** 0.532 (6.01) *** 0.178 (1.96)** 
Cash Flow 0.12 (4.14) *** 0.058 (1.90)* 0.062 (2.00)** 0.041 (1.65) 0.027 (0.44) 
NEWSALES 0.08 (2.49) *** -0.020 (-4.43)*** -0.022 (4.08)*** -0.007 (-1.26) 0.003 (0.52) 
SALES – – -3.44e-06 (0.64) -2.57e-05 (-3.29)*** -4.38e-06 (1.44) 
SURPRISE – – 0.014 (0.59) 0.083 (1.39) 0.007 (0.25) 
ρ –   0.575  
RDSt-1     0.948 (7.74)*** 
R2 within 0.92 0.444 0.457 0.279  
N 164 179 179 179 164 
F/Χ2 141.0 42.85 25.66 18.89 67.00 
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Prob > F/Χ2 0.000 0.000 0.000 0.000 0.000 
Note: G&V (2000) … Grabowski and Vernon (2000). 
t-values (Model 1-3), z-values (Model 4) in parentheses. 
* significant at the 0.10 level, ** 0.05 level, *** 0.01-level. 
The constant is the expected value of all firm-specific αi. Individual values are not reported. 
There are two substantive explanations for this discrepancy (differences due to alternative 
estimation approaches will be dealt with separately below). First, industry profit margins 
have been higher in the U.S. (24-29% in the period 1980-1994) than in Japan (15-22% during 
the observation period). Second, as pointed out in Section 0, Japanese drug firms spend about 
three times as much on marketing as on R&D. Accordingly, marketing budgets may be the 
first to respond to changes in economic conditions while R&D budgets may be relatively 
more autonomous. However, this point has to remain speculative as we do not have 
disaggregated data on firm spending. 
 
Parameter estimates for the NEWSALE variable are less robust and small in absolute size. In 
Models 1 and 2, the coefficient of the NEWSALE variable is in the range of -0.02, about one 
quarter of the value estimated by Grabowski and Vernon. It is significant at the 0.01 level and 
has the correct sign, as our index of R&D productivity has declined over time (see Figure 4). 
This fall is most probably the result of Japanese health policy, which attempts to attack 
exploding health costs by reducing the costs of new drugs. As a result, margins on new drugs 
are considerably lower than in the U.S. However, the coefficient value slumps in absolute 
value and loses statistical significance in Model 3, which controls for first-order serial 
correlation, as well as in the dynamic Model 4. The latter results suggest that sales generated 
by newly introduced drugs have no substantial impact on the R&D investment behaviour of 
Japanese pharmaceutical firms. 
 
Taken together, these results confirm our first hypothesis, which stated that institutional 
differences in the way innovation in the pharmaceutical industry is rewarded in Japan would 
mute the incentive effect of expected profits.  
 
Coefficient estimates for the cash flow variable are also not robust to differences in model 
specification. For Models 1 and 2, which closely resemble the reference model, estimates are 
significant, albeit only at the 0.1 level in Model 1. In absolute terms, parameter estimates 
range from 0.058 to 0.062, i.e. a 1% increase (decrease) in the cash flow-to-sales ratio is 
estimated to increase (decrease) R&D expenditures by approximately 0.06%. This is about 
half the size of the effect found for the U.S. In Models 3 and 4, the coefficients for the cash 
flow variable are no longer significantly different from zero. These results confirm our second 
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hypothesis which stated that thanks to institutional differences in the financial system, 
Japanese pharmaceutical firms would face smaller financial constraints than their U.S. peers. 
In fact, Models 3 and 4 indicate that they are not subject to any external financial constraint. 
Although none of the firms included in our sample is part of a keiretsu, they nevertheless 
appear to have sufficiently close ties to banks and hence lower costs of external funding, 
which allows them to smooth out hikes in the availability of internal funding. This result is in 
line with the study by Hall et al. (1999). 
 
Of the control variables, coefficient estimates for SALES are tiny in absolute value in all 
specifications and only statistically significant in Model 3. To the extent that there is any link 
between firm size and R&D intensity, the negative sign suggests that R&D intensity declines 
marginally with firm size. The coefficient of the SURPRISE variable, which attempts to 
capture the specificities of the way drug prices are set in Japan, is never significantly different 
from zero. 
 
The coefficient of the lagged dependent variable in Model 4 shows that R&D investment is 
indeed quite sluggish, as theoretical considerations suggest (see Section 0). Apart from the 
fact that firms may be unable to precisely tailor their R&D budgets to changes in external 
conditions and that they may want to hold on to their intangible assets, which are embodied in 
their R&D personnel, the result ties in with a broader question: Given the current 
unfavourable regulatory environment, why do Japanese firms continue to step up investment 
in R&D? 
 
Apart from having to maintain their absorptive capacity (see Cohen and Levinthal 1989, 
1990), there is another and possible more important reason: An overwhelming share of profits 
in the pharmaceutical industry is generated by new drugs and Japanese pharmaceutical firms 
want to stay in business. As argued by Sharp and Patel (1997), a high current R&D intensity 
may not necessarily be a sign of innovative success. Instead, it may be a response to past 
failure in an attempt to move to virtuous cycle in which intensive R&D leads to a high 
number of successful products. So as not to fall further behind their international rivals, 
Japanese firms have to match their R&D efforts. 
 
Our results also raise methodological questions. Differences in model specification were 
shown to impact estimation results quite strongly. Of the three main explanatory variables 
considered, only industry profit margin remained significant after controlling for first-order 
serial correlation and autonomous R&D investment behaviour. This is an important result, as 
it conforms to theoretical expectations. However, it casts doubt on the validity of the results 
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obtained in the reference paper (Grabowski and Vernon 2000), which controls for neither 
effect. Replicating their study with more sophisticated estimation techniques might affect 
results in a similar manner as in this paper and yield qualitatively different results. 
 
A final interesting point is the impact of turbulences in Japanese financial markets during our 
observation period. As is well-known, Japanese stock markets rallied until 1991. Since then, 
stock prices have fallen more or less consistently for the rest of the 1990ies. Splitting the data 
set into the period 1987-1991, when the bubble burst, and 1992-1998, and repeating the above 
estimations refine our findings. For the post-1991 period, parameter estimates remain more or 
less unchanged (significance decreases, which is to be expected from a lower n). For the 
period up to 1991, however, the INDMARG variable becomes significantly negative. In other 
words, even though profit margins were decreasing at that time, the general euphoria driving 
the bubble in the stock market appears to have induced managers in the pharmaceutical 
industry to further step up investment in R&D. 
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SUMMARY AND IMPLICATIONS FOR FUTURE RESEARCH 
In this paper, we have tested and extended a static panel data model developed by Grabowski 
and Vernon (2000) to explain R&D expenditures in the U.S. pharmaceutical industry for the 
15 publicly listed Japanese pharmaceutical firms over the period 1987 to 1998. Akin to 
Grabowski and Vernon (2000), we find expected returns to be an important determinant of 
R&D investment. However, the effect is considerably smaller in Japan and sensitive to 
econometric model specification, above all in a theoretically more appealing dynamic panel 
data model. This is particularly obvious in the case of returns from newly introduced drugs, 
which cease to be significant in more sophisticated model specifications. Substantively, this is 
an alarming result, as it clearly highlights the dangerous incentive effect of recent regulatory 
attempts to curb an exploding public health bill. Unless Japanese firms are adequately 
rewarded for developing and marketing innovative drugs, they may lose out to their 
international rivals in an industry driven by innovative success. 
 
Moreover, we find that Japanese pharmaceutical firms face smaller financial constraints than 
their US rivals. Depending on the model specification, constraints are either small or non-
binding. Similar results have been obtained in other studies and can be explained by the closer 
relationship between firms and sources of external finance in a bank-based financial system. 
Finally, the sensitivity of our results to different model specification highlights the risk of 
obtaining misleading estimation results. Firm-level data on R&D investment is characterised 
by considerable serial correlation, while R&D investment is subject to high adjustment costs. 
These features suggest that dynamic panel data models are the most appropriate modelling 
framework, while static models should control for serial correlation. In both cases, estimation 
results may differ substantially from simple static panel data models. 
 
There are a number of ways how the research reported in this paper could be extended and 
taken further. For Japan, the model could be extended to look at the relationship between 
marketing expenditures and successful new drug innovations in Japan. Since marketing 
expenditures are the single largest cost component of Japanese drug firms, they might be 
much more responsive to changes in economic fortunes than R&D expenditures. Also, it 
would be worthwhile re-estimating the data used in Grabowski and Vernon (2000), 
implementing the econometric refinements employed in this paper. This may have a 
significant impact on their results, possibly leading to qualitatively different conclusions. 
Finally, it would be interesting to conduct similar studies in other major drug markets, such as 
the European Union, as well as for more recent or longer periods of time. 
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